Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.92 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)820.04K
Market Cap
$578.38M
Enterprise Value$505.19M
Total Cash (Recent Filing)$20.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 15, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding77,014,780
10 Day Avg. Volume1,094,311
30 Day Avg. Volume820,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-190.28
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$22.14Price Target Upside194.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRP1 + Opdivo achieved an objective response rate (ORR) of 33.6%, which is significantly higher than what would be expected with an anti-PD1 agent alone in an anti-PD1-refractory melanoma population.
Financial StabilityReplimune's improved cash balance further solidifies the company's position heading into the potential launch of RP1.
Regulatory ApprovalThe FDA granted breakthrough therapy designation for RP1 + nivolumab in anti-PD-1-failed melanoma.
Bears Say
Development CostsReplimune guides to sufficient cash runway to fund operations into 4Q26, accounting for the costs associated with scaling up for the potential commercialization of RP1 in skin cancers.
Market CompetitionReplimune's RP1 + Opdivo combination therapy shows potential differentiation against other treatments like Amtagvi™ due to its efficacy and safety profile.
Regulatory ProcessThe FDA has accepted REPL's BLA for RP1 and granted priority review, with a PDUFA date set for July 22, 2025.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.92 and its highest was $17.00 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $578.38M.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is May 15, 2025 which is in 29 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Feb 06, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.706 by -$0.084.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.75.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 77,014,780 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.706. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
---
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (194.81% Upside)
$22.14 (194.81% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 37.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $134.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.18%
12-Months-Change
Fundamentals
Return on Equity
-50.50%
Trailing 12-Months
Asset Growth
13.27%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
---
REPL Stock 12 Month Forecast
Average Price Target
$22.14
▲(194.81% Upside)
Technical Analysis
Chimerix
―
Xencor
―
Rocket Pharmaceuticals
―
Intellia Therapeutics
―
Praxis Precision Medicines
―
Best Analysts Covering REPL
1 Year
1 Year Success Rate
7/19 ratings generated profit
1 Year Average Return
-5.30%
reiterated a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of -5.30% per trade.
---